Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2025-04-22 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC
Regulatory Filings
2025-04-22 English
Enhertu combination improved PFS in 1L HER2+ mBC
Earnings Release Classification · 99% confidence The document is an official announcement disseminated via RNS (RNS Number : 5592F) on April 22, 2025, concerning positive Phase III trial results (DESTINY-Breast09) for the drug Enhertu. It contains key clinical data, quotes from management, and notes about the trial design. This format—a press release detailing significant operational or clinical updates, often marked as containing 'inside information' and distributed through a regulatory news service—is characteristic of a general regulatory announcement rather than a comprehensive periodic report (like 10-K or IR) or a specific financial filing. Since it is a broad, material announcement distributed via RNS that doesn't fit the specific categories like ER (Earnings Release) or CAP (Capital Update), the most appropriate classification is the general regulatory filing category. Q2 2025
2025-04-22 English
RESULT OF AGM
Regulatory Filings
2025-04-11 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement from AstraZeneca PLC detailing the results of its Annual General Meeting (AGM) held on 11 April 2025. It provides a comprehensive table of voting results for various resolutions, including the re-election of directors and approval of remuneration. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2025-04-11 English
Special Business Approved at AGM
AGM Information Classification · 99% confidence The document explicitly states it contains the 'RESOLUTIONS OF ASTRAZENECA PLC' passed at an 'Annual General Meeting' held on 'Friday 11 April 2025'. The content details specific resolutions (8 through 12) concerning the authorization to allot shares (Section 551, 570, 573 of the Companies Act 2006) and authority for market purchases of ordinary shares (share buybacks). This content is characteristic of the formal documentation resulting from an AGM, specifically detailing the shareholder votes and authorizations granted. Since the document lists the resolutions passed at the AGM, the most appropriate classification is AGM Information (AGM-R). It is not a proxy statement (PSI) as it reports the results, nor is it a general earnings release or annual report.
2025-04-11 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-10 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.